Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Ionis Pharmaceuticals Inc News

    42,06 $ +2,41% +0,99 $
    In : 39,300 € | 17:20:06 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2ACMZ
    ISIN: US4622221004
    US-Symbol: IONS
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 5,41
    MB8MJC

    Ionis Pharmaceuticals Inc News

    07:05 Uhr - PR Newswire
    Ionis to hold first quarter 2024 financial results webcast
    Ionis to hold first quarter 2024 financial results webcast PR Newswire
    07.04.24 - PR Newswire
    Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
    Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire
    01.04.24 - PR Newswire
    Ionis to present at upcoming investor conferences
    Ionis to present at upcoming investor conferences PR Newswire
    28.03.24 - PR Newswire
    Ionis to hold olezarsen Phase 3 data webcast
    Ionis to hold olezarsen Phase 3 data webcast PR Newswire
    25.03.24 - PR Newswire
    Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
    Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire
    13.03.24 - PR Newswire
    Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
    Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire
    29.02.24 - PR Newswire
    Ionis announces new chief global product strategy officer to lead next phase of commercial growth
    Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR Newswire
    28.02.24 - PR Newswire
    Ionis to present at upcoming investor conferences
    Ionis to present at upcoming investor conferences PR Newswire
    21.02.24 - PR Newswire
    Ionis reports fourth quarter and full year 2023 financial results
    Ionis reports fourth quarter and full year 2023 financial results PR Newswire
    15.02.24 - PR Newswire
    Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
    Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire
    08.02.24 - PR Newswire
    Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
    Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-​mediated amyloid cardiomyopathy PR Newswire
    07.02.24 - PR Newswire
    Ionis to hold fourth quarter and full year 2023 financial results webcast
    Ionis to hold fourth quarter and full year 2023 financial results webcast PR Newswire
    22.01.24 - 4investors
    Ionis Pharma will Zulassung in den USA für Donidalorsen beantragen
    22.01.24 - PR Newswire
    Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
    Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema PR Newswire
    08.01.24 - PR Newswire
    Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
    Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases PR Newswire
    22.12.23 - 4investors
    Ionis Pharmaceuticals: FDA-Zulassung für Wainua zur Behandlung von hATTR-PN
    21.12.23 - PR Newswire
    WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
    WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-​mediated amyloidosis PR Newswire
    20.12.23 - PR Newswire
    Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
    Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
    18.12.23 - PR Newswire
    Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
    Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema PR Newswire
    14.12.23 - PR Newswire
    Ionis announces the appointment of Michael Yang to Board of Directors
    Ionis announces the appointment of Michael Yang to Board of Directors PR Newswire

    Newssuche

    Videos

    newspaper
    09:10 Uhr -3,11%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »